Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Bloomberg Customers

Genmab Shares Fall Most Since March 2010 After Updating Guidance

Genmab A/S fell the most since March 2010 in Copenhagen trading after the company updated its financial forecasts to reflect a lower value of a manufacturing facility that had been expected to be sold this year.

The shares declined 7.4 percent to 29 kroner as of 9:13 a.m. The stock dropped as much as 19 percent, the biggest intraday slide since March 8, 2010.

“The execution of a sale of the manufacturing facility is still one of our top priorities, but due to worsening market conditions we have decided to reduce the fair value of teh facility and move an anticipated sale into next year,” the Danish biotechnology company said in a statement released after the close of Copenhagen trading yesterday.

Genmab will host a conference call today at 3 p.m. Copenhagen time to discuss financial results for the first nine months of the year.

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.